News42 seconds ago
NMPA accepted Akeso’s ebronucimab (PCSK9) marketing application in two cardiovascular indications
HONG KONG, June 1, 2023 /PRNewswire/ — Akeso Inc. (9926. HK, “Akeso”) announced today that China’s National Medical Products Administration (NMPA) has accepted its New Drug Application...
